483 sent to Jilin Shulan Synthetic Pharmaceutical Co.
Abstract:Warning letter sent to Jilin Shulan Synthetic Pharmaceutical Co. regarding significant deviations from Current Good Manufacturing Practice (CGMP) for the manufacture of APIs.
Compliance Trainings
Transfer of Analytical Methods According to the USP Chapter <1224>
By - Dr. Ludwig Huber
On Demand Access Anytime
By - Dr. Ludwig Huber
On Demand Access Anytime
4-Hour Virtual Training: Auditing the Microbiology Laboratory
By - Robert D Seltzer
On Demand Access Anytime
By - Robert D Seltzer
On Demand Access Anytime
Microbiological Risk: Do I Really Need to Test Raw Materials for Microorganisms
By - Henry Urbach
On Demand Access Anytime
By - Henry Urbach
On Demand Access Anytime
Compliance Standards
You Recently Viewed
